



thor medical

Thor Medical ASA: Mechanical Completion Achieved at Herøya Facility, AlphaOne

17.4.2026 07:00:00 CEST | Thor Medical ASA | Non-regulatory press releases

Thor Medical, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, today announced that its AlphaOne production facility at Herøya Industrial Park has reached mechanical completion. The plant is now fully constructed, on time and budget, and progressing as planned toward production start in the third quarter this year.

“This is a major achievement for Thor Medical and a testament to the strong execution capabilities of our team and partners,” said Jasper Kurth, Chief Executive Officer of Thor Medical ASA.

Mechanical completion confirms that all major construction and installation activities have been finalized in accordance with project specifications. The facility has now entered the commissioning phase, which partly commenced already in March. During commissioning, systems and equipment are being tested, verified, and prepared for operational start-up. Commissioning activities are expected to continue toward production start in the third quarter this year.

“Reaching Mechanical Completion, alongside the successful start of commissioning, keeps us firmly on track toward commencing production in the third quarter and delivering on our strategy to become a leading supplier of alpha-emitting radioisotopes for cancer treatment,” Kurth added.

The AlphaOne facility at Herøya Industrial Park will play a central role in Thor Medical's mission to address the growing global demand for radiopharmaceuticals.

Contacts

- Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reierth@thormedical.com

About Thor Medical ASA

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium, a key component of next-generation targeted cancer treatment. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides a reliable, environmentally friendly and cost-efficient supply of alpha emitters to the radiopharmaceutical industry. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by fueling next-generation cancer therapies with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com - <https://www.thormedical.com>.

Attachments

- [Download announcement as PDF.pdf](#)